We rank companies based on fund manager, research analyst and news sentiment
ANIX stock icon

Anixa Biosciences
ANIX

$3.1
1.64%
 

About: Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Employees: 6

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 3 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

33% more capital invested

Capital invested by funds: $12.8M [Q3] → $17.1M (+$4.22M) [Q4]

4% more funds holding

Funds holding: 49 [Q3] → 51 (+2) [Q4]

1.51% more ownership

Funds ownership: 12.64% [Q3] → 14.16% (+1.51%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 12

62% less call options, than puts

Call options by funds: $80.3K | Put options by funds: $210K

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$12
287%
upside
Avg. target
$12
287%
upside
High target
$12
287%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Yi Chen
287%upside
$12
Buy
Reiterated
21 Mar 2024
HC Wainwright & Co.
Yi Chen
287%upside
$12
Buy
Reiterated
13 Feb 2024
HC Wainwright & Co.
Yi Chen
287%upside
$12
Buy
Reiterated
7 Dec 2023

Financial journalist opinion